Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Erasca, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ROBUST MONOTHERAPY EFFICACY AND GENERALLY WELL-TOLERATED SAFETY RESULTS OBSERVED DURING DOSE ESCALATION FOR ERAS-0015 IN BOTH KRAS G12X NSCLC AND PDAC REINFORCE BEST-IN-CLASS POTENTIAL ACROSS RAS-TARGETED AGENTS

ERASCA REPORTS FIRST QUARTER 2026 BUSINESS UPDATES AND FINANCIAL RESULTS

ERAS-0015, A POTENTIALLY BEST-IN-CLASS PAN-RAS MOLECULAR GLUE, IS BEING EVALUATED IN COMBINATION WITH PEMBROLIZUMAB ERAS-0015, A POTENTIALLY BEST-IN-CLASS PAN-RAS MOLECULAR GLUE, IS BEING EVALUATED IN COMBINATION WITH PEMBROLIZUMAB

ERASCA ANNOUNCES CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK TO EVALUATE ERAS-0015 IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB)

NEW YORK, MAY 7, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ERASCA, INC. ("ERASCA" OR THE "COMPANY") (NASDAQ:ERAS). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ERASCA, INC. - ERAS

SAN DIEGO, MAY 06, 2026 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED ITS PARTICIPATION IN THE BANK OF AMERICA SECURITIES 2026 HEALTH CARE CONFERENCE BEING HELD AT THE ENCORE HOTEL IN LAS VEGAS, NEVADA. MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT ON WEDNESDAY, MAY 13, 2026, AT 3:00 PM PACIFIC TIME AND WILL ALSO PARTICIPATE IN ONE-ON-ONE INVESTOR MEETINGS.

ERASCA TO PRESENT AT THE BANK OF AMERICA SECURITIES HEALTH CARE CONFERENCE

SAN DIEGO, APRIL 28, 2026 (GLOBE NEWSWIRE) -- JOHNSON FISTEL, PLLP IS INVESTIGATING POTENTIAL CLAIMS ON BEHALF OF INVESTORS OF ERASCA, INC. (NASDAQ: ERAS). THE INVESTIGATION FOCUSES ON ERASCA'S EXECUTIVE OFFICERS AND WHETHER INVESTOR LOSSES MAY BE RECOVERED UNDER FEDERAL SECURITIES LAWS.

ERASCA, INC. SHAREHOLDERS ARE ENCOURAGED TO REACH OUT TO JOHNSON FISTEL FOR MORE INFORMATION ABOUT POTENTIALLY RECOVERING THEIR LOSSES

BLOCK & LEVITON IS INVESTIGATING ERASCA INC. ($ERAS) FOR POSSIBLE SECURITIES FRAUD. INVESTORS WHO LOST MONEY SHOULD CONTACT THE FIRM TO RECOVER LOSSES.

ERASCA, INC. INVESTIGATED FOR SECURITIES FRAUD; BLOCK & LEVITON ENCOURAGES INVESTORS TO CONTACT THE FIRM TO POSSIBLY RECOVER LOSSES

ROBUST MONOTHERAPY EFFICACY IN KRAS G12X NSCLC: 62% UORR IN 2L+ AND 75% UORR IN POST-ICI/PLATINUM 2/3L AT 16-32 MG QD PAD, AND 64% UORR IN 2L+ AT 24-32 MG QD RDE

ERASCA ANNOUNCES POSITIVE PRELIMINARY PHASE 1 DOSE ESCALATION DATA FOR POTENTIALLY BEST-IN-CLASS PAN-RAS MOLECULAR GLUE ERAS-0015 IN KRAS-MUTANT SOLID TUMORS

SAN DIEGO, APRIL 27, 2026 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED THAT THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST TO DISCUSS PRELIMINARY PHASE 1 DOSE ESCALATION DATA FOR ITS POTENTIALLY BEST-IN-CLASS PAN-RAS MOLECULAR GLUE ERAS-0015 IN PATIENTS WITH RAS-MUTANT SOLID TUMORS TODAY, MONDAY, APRIL 27, 2026, AT 4:30 PM ET. CONFERENCE CALL AND WEBCAST INFORMATION ERASCA WILL HOLD A CONFERENCE CALL AND WEBCAST MONDAY, APRIL 27, 2026, AT 4:30 PM ET.

ERASCA TO HOST CONFERENCE CALL AND WEBCAST TO DISCUSS PRELIMINARY PHASE 1 DOSE ESCALATION DATA FOR POTENTIALLY BEST-IN-CLASS PAN-RAS MOLECULAR GLUE ERAS-0015

ENCOURAGING EARLY CLINICAL ACTIVITY OBSERVED DURING ERAS-0015 DOSE ESCALATION, INCLUDING ONGOING RESPONSES ACROSS MULTIPLE RAS-MUTANT TUMORS WITH FAVORABLE SAFETY, TOLERABILITY, AND PHARMACOKINETICS

ERASCA REPORTS FOURTH QUARTER AND FULL YEAR 2025 BUSINESS UPDATES AND FINANCIAL RESULTS

WORLDWIDE RIGHTS POSITION ERASCA TO ADVANCE ERAS-0015 THROUGH A UNIFIED GLOBAL DEVELOPMENT STRATEGY ERAS-0015'S PROMISING EARLY CLINICAL DATA UNDERSCORE ITS POTENTIAL TO BE A BEST-IN-CLASS RAS-TARGETING AGENT INITIAL PHASE 1 MONOTHERAPY DATA FOR ERAS-0015 EXPECTED IN H1 2026 SAN DIEGO, MARCH 10, 2026 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED THE EXERCISE OF ITS OPTION TO EXPAND THE EXISTING LICENSE AGREEMENT WITH JOYO PHARMATECH CO., LTD. (JOYO) TO INCLUDE CHINA, HONG KONG, AND MACAU, WHICH WILL PROVIDE ERASCA WITH WORLDWIDE RIGHTS TO ITS POTENTIAL BEST-IN-CLASS PAN-RAS MOLECULAR GLUE ERAS-0015.

ERASCA EXERCISES OPTION TO SECURE WORLDWIDE RIGHTS FOR ERAS-0015 PAN-RAS MOLECULAR GLUE TO INCLUDE CHINA, HONG KONG, AND MACAU

ERAS-0015, A PAN-RAS MOLECULAR GLUE, WILL BE EVALUATED IN COMBINATION WITH PRMT5 INHIBITOR VOPIMETOSTAT TANGO WILL SPONSOR THE CLINICAL TRIAL AND ERASCA WILL SUPPLY ERAS-0015 AT NO COST SAN DIEGO, MARCH 05, 2026 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (CTCSA) WITH TANGO THERAPEUTICS, INC. (NASDAQ: TNGX; TANGO) TO EVALUATE ERASCA'S PAN-RAS MOLECULAR GLUE, ERAS-0015, WITH TANGO'S PRMT5 INHIBITOR, VOPIMETOSTAT (TNG462). WE'VE DISCLOSED ENCOURAGING EARLY CLINICAL ACTIVITY FOR OUR POTENTIAL BEST-IN-CLASS MOLECULAR GLUE, ERAS-0015, INCLUDING FIRST CLINICAL RESPONSES IN MULTIPLE PATIENTS WITH DIFFERING TUMOR TYPES AND RAS MUTATIONS AT JUST 1/10TH OF THE DOSE AT WHICH FIRST CLINICAL RESPONSES WERE OBSERVED WITH RMC-6236, SAID JONATHAN E.

ERASCA AND TANGO THERAPEUTICS ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATION OF ERAS-0015 AND VOPIMETOSTAT

THE ISSUED PATENT PROVIDES INTELLECTUAL PROPERTY PROTECTION FOR ERAS-4001 AND RELATED COMPOSITIONS UNTIL AT LEAST 2043 EXPANDS ERASCA'S DIVERSIFIED IP PORTFOLIO FOR RAS-DRIVEN CANCERS INITIAL PHASE 1 MONOTHERAPY DATA EXPECTED FOR ERAS-0015 IN 1H AND FOR ERAS-4001 IN 2H 2026 SAN DIEGO, FEB. 24, 2026 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED THAT THE U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED PATENT NO. 12,552,813, TITLED HETEROCYCLIC SUBSTITUTED PYRIMIDOPYRAN COMPOUND AND USE THEREOF.

Erasca, Inc.

ERAS

Price

Financial Reports

No items found.

Press Releases

Erasca, Inc.

ERAS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ERAS